Active substances: Gabapentin
Subsequently, we could receive payment for achievement of certain clinical development and regulatory milestones pursuant to the existing agreement. Both parties retain certain termination rights. The key elements of our strategy are to: Pursue development and commercialization of our lead product candidates.
We have five product candidates undergoing DOV-driven or collaborative clinical development. These product candidates address four separate and substantial pharmaceutical markets: insomnia, pain, depression and alcohol abuse.
We have designed the clinical programs for the product candidates we are developing in an effort to provide clear and defined paths to attain regulatory approval. We intend to continue to devote substantial resources to completing clinical testing and commercializing these product candidates.
Expand our product candidate portfolio with novel drug candidates that address unmet needs in large, established markets. We seek to identify and develop, either internally or through collaborative agreements, novel drug candidates that address unmet needs in large, established markets.
For example, our product candidates for the treatment of pain and insomnia, bicifadine and indiplon, respectively, have demonstrated positive results equivalent to, or better than, currently marketed products.
We intend to continue expanding our existing product candidate portfolio by discovering and developing novel drug compounds both internally and through focused outsourced research and development.
We also intend to expand our portfolio by identifying, in-licensing and developing additional compounds that are potentially superior to currently marketed products and by developing additional applications and formulations for our existing discovery and licensed compounds.
We have built and intend to continue to build a portfolio of diverse product candidates to address CNS disorders to reduce the risks associated with the clinical development of any one drug.
The tablet can be divided into equal halves. Epilepsy, the usual dose is: Adults and adolescents: Take the number of capsules or tablets as instructed.Strengths: 100 mg, 300 mg, 400 mg Brand: Neurontin Strengths: 100 mg, 300 mg, 400 mg Dosage for postherpetic neuralgia Adult dosage ages 18-64 years Typical starting dosage: Day 1, 300 mg; day 2, 600 mg 300 mg two times per day, spaced evenly throughout the day; day 3, 900 mg 300 mg, three times per day, spaced evenly throughout the day.
Your doctor will usually build up your dose gradually. The starting dose will generally be between 300 mg and 900 mg each day. The treatment is started with a low initial dose which is gradually increased over a period of approximately 3 days.